FORTIS PHARMA CONSULTING LIMITED
Get an alert when FORTIS PHARMA CONSULTING LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-06-30 (in 1mo)
Last filed for 2024-09-30
Confirmation statement due
2027-02-06 (in 9mo)
Last made up 2026-01-23
Watchouts
None on the register
Cash
£517K
+38.6% vs 2023
Net assets
£7M
+31.1% highest in 6 filed years
Employees
21
-8.7% vs 2023
Profit before tax
£2M
-17.4% vs 2023
Net assets
10-year trend · vs Industrials median
Accounts
10-year trend · latest reflected 2024-09-30
| Metric | Trend | 2020-03-31 | 2020-04-01 | 2021-03-31 | 2021-04-01 | 2021-09-30 | 2021-10-01 | 2022-09-30 | 2022-10-01 | 2023-09-30 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | — | — | £3,038,583 | — | £2,069,359 | — | £4,245,114 | — | £4,294,409 | £3,409,128 | |
| Operating profit | — | — | £1,972,031 | — | £1,209,501 | — | £2,046,309 | — | £2,120,844 | £1,756,194 | |
| Profit before tax | — | — | £1,972,580 | — | £1,209,325 | — | £2,046,317 | — | £2,121,010 | £1,753,006 | |
| Net profit | — | — | — | — | — | — | — | — | £2,121,992 | £1,723,489 | |
| Cash | £445,570 | — | £1,525,130 | — | £693,805 | — | £1,116,922 | — | £373,061 | £516,994 | |
| Total assets less current liabilities | £765,044 | — | £1,958,765 | — | £1,266,839 | — | £3,426,138 | — | £5,547,775 | £7,271,264 | |
| Net assets | £764,242 | — | £1,941,738 | — | £1,264,697 | — | £3,425,783 | — | £5,547,775 | £7,271,264 | |
| Equity | £764,242 | — | £1,941,738 | — | £1,264,697 | — | £3,425,783 | — | £5,547,775 | £7,271,264 | |
| Average employees | 9 | — | 9 | — | 13 | — | 18 | — | 23 | 21 | |
| Wages | — | — | — | — | £394,160 | — | £986,033 | — | £1,169,722 | £1,019,544 | |
| Directors' remuneration | — | — | — | — | £30,017 | — | £108,312 | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Year-on-year
FY2023 → FY2024 · period ending 2024-09-30 vs 2023-09-30
-
Turnover
-20.6%
£4,294,409 £3,409,128
-
Cash
+38.6%
£373,061 £516,994
-
Net assets
+31.1%
£5,547,775 £7,271,264
highest in 6 filed years
-
Employees
-8.7%
23 21
-
Operating profit
-17.2%
£2,120,844 £1,756,194
-
Profit before tax
-17.4%
£2,121,010 £1,753,006
-
Wages
-12.8%
£1,169,722 £1,019,544
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2020-03-31 | 2020-04-01 | 2021-03-31 | 2021-04-01 | 2021-09-30 | 2021-10-01 | 2022-09-30 | 2022-10-01 | 2023-09-30 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | — | — | 64.9% | — | 58.4% | — | 48.2% | — | 49.4% | 51.5% | |
| Net margin | — | — | — | — | — | — | — | — | 49.4% | 50.6% | |
| Return on capital employed | — | — | 100.7% | — | 95.5% | — | 59.7% | — | 38.2% | 24.2% | |
| Current ratio | — | — | — | — | — | — | — | — | 13.20x | 12.54x | |
| Interest cover | — | — | — | — | 5678.41x | — | — | — | — | 550.19x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102 §1A
- Reporting scope
- Standalone (parent only)
- Auditor
- Forvis Mazars LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The Company has net current assets of £7,271,264 (2023: £5,543,198) and net assets of £7,271,264 (2023: €5,547,775) at 30 September 2024. Therefore, the directors believe it is appropriate to prepare the accounts to 30 September 2024 on a going concern basis and there will be no adverse effect on solvency for more than 12 months after the date of approval of the financial statements.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
2 active · 8 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| MAXWELL, James | Director | 2024-02-15 | Dec 1984 | British |
| SILVER, Gabrielle Alison | Director | 2024-02-15 | Sep 1973 | British |
Show 8 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| BENNETT, Stephen William | Secretary | 2012-06-07 | 2021-07-13 |
| SMITH, Edward James | Secretary | 2005-03-12 | 2012-06-07 |
| M W DOUGLAS & COMPANY LIMITED | Corporate Nominee Secretary | 2005-03-12 | 2005-03-12 |
| CHAFFER, Daniel | Director | 2021-07-13 | 2023-07-14 |
| MEDLEY, Andrew John | Director | 2021-07-13 | 2024-04-19 |
| SMITH, Graeme David | Director | 2005-03-12 | 2022-09-01 |
| STANTON, Matthew James | Director | 2012-06-07 | 2019-11-07 |
| DOUGLAS NOMINEES LIMITED | Corporate Nominee Director | 2005-03-12 | 2005-03-12 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Azimuth Pharma Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 76 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-05-01 | MR01 | mortgage | Mortgage create with deed with charge number charge creation date | |
| 2026-02-05 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-06-27 | AA | accounts | Accounts with accounts type full | |
| 2025-02-07 | CH01 | officers | Change person director company with change date | |
| 2025-02-06 | CH01 | officers | Change person director company with change date | |
| 2025-02-06 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2025-02-06 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-09-30 | AA | accounts | Accounts with accounts type full | |
| 2024-09-24 | AD01 | address | Change registered office address company with date old address new address | |
| 2024-05-13 | AP01 | officers | Appoint person director company with name date | |
| 2024-05-10 | TM01 | officers | Termination director company with name termination date | |
| 2024-05-10 | AP01 | officers | Appoint person director company with name date | |
| 2024-02-07 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-02-06 | CH01 | officers | Change person director company with change date | |
| 2024-01-23 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2023-09-05 | TM01 | officers | Termination director company with name termination date | |
| 2023-06-21 | AA | accounts | Accounts with accounts type full | |
| 2023-02-06 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2022-09-15 | TM01 | officers | Termination director company with name termination date | |
| 2022-07-11 | AA | accounts | Accounts with accounts type full |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 3
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.